Cargando…
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. METHODS: We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascul...
Autor principal: | Antithrombotic Trialists' (ATT) Collaboration |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Lancet Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715005/ https://www.ncbi.nlm.nih.gov/pubmed/19482214 http://dx.doi.org/10.1016/S0140-6736(09)60503-1 |
Ejemplares similares
-
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy
por: Cholesterol Treatment Trialists’ Collaboration,
Publicado: (2022) -
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
por: Cholesterol Treatment Trialists' (CTT) Collaboration
Publicado: (2010) -
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
por: Cholesterol Treatment Trialists' (CTT) Collaborators
Publicado: (2012) -
Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000) -
Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis
por: Judge, Conor, et al.
Publicado: (2019)